1/7
Elementos traza y factores de crecimiento en el período perinatal / NM Diaz Gomez; E Domenech Martinez; F Barroso Guerrero.-- p.351-356.-- En: Anales Españoles de Pediatría.-- 44, 4 (1996)
COBRE   CINC   RECIEN NACIDO   CRECIMIENTO   PERINATOLOGIA   PROTEINAS DE ENLACE DE FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3731
Tipo de Material:
Separata




2/7
The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa / M Hotta; I Fukuda; K Sato; N Hizuka; T Shibasaki; K Takano.-- p. 200-6.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 85, 1 (2000)
ADOLESCENTE   ADULTO   ANOREXIA NERVIOSA   MARCADORES BIOLOGICOS   INDICE DE MASA CORPORAL   PESO CORPORAL   REABSORCION OSEA   HUESOS   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA 2 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINAS DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   ESTADO NUTRICIONAL   OSTEOCALCINA   NUTRICION PARENTERAL TOTAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-3802
Tipo de Material:
Separata

    Malnutrition is one of the risk factors for bone loss in patients with anorexia nervosa (AN). To clarify the effects of nutritional status on bone metabolism, we examined the relationship between serum levels of nutritional indicators [insulin-like growth factor I (IGF-I), IGF-binding protein-2 (IGFBP-2), and IGFBP-3] and markers for bone metabolism [serum osteocalcin and urinary excretion of C-terminal telopeptide of collagen type I (CrossLaps)] in 45 AN out-patients, including 8 severely malnourished patients who required hospitalization and iv hyperalimentation (IVH). Compared to healthy subjects, serum IGF-I and IGFBP-3 were lower, whereas IGFBP-2 was higher in out-patients who had a body mass index (BMI) less than 16.5 kg/m2. In these patients, urinary excretion of CrossLaps, a marker of bone resorption, was higher, whereas serum osteocalcin, a marker of bone formation, was lower than those in control subjects. All of these parameters were normal in patients whose BMI ranged from 16.5-18.5 kg/m2. Serum levels of osteocalcin correlated positively with BMI (r = 0.512; P<0.0001), IGF-I (r = 0.558; P<0.0001), and IGFBP-3 (r = 0.369; P<0.001) in AN out-patients. In the 8 severely malnourished AN patients, serum levels of IGF-I and osteocalcin significantly increased 3 and 7 days, respectively, after the start of a 5-week IVH therapy regimen and reached normal levels within 5 weeks, accompanied by still elevated urinary excretion of CrossLaps. The present study demonstrates that an improvement in nutritional status in AN patients during IVH therapy rapidly increases the serum IGF-I levels, followed by a progressive increase in osteocalcin, suggesting immediate start of bone formation. However, increased bone resorption appears to continue for at least 5 weeks.




3/7
Growth and growth factors in premature infants receiving dexamethasone for bronchopulmonary dysplasia / AM Skinner; M Battin; A Solimano; J Daaboul; HF Kitson.-- p.539-546.-- En: American Journal of Perinatology.-- 14, 9 (1997)
CONSTITUCION CORPORAL   DISPLASIA BRONCOPULMONAR   ESTUDIO COMPARATIVO   DEXAMETASONA   INGESTION DE ENERGIA   GLUCOCORTICOIDES SINTETICOS   NUTRICION DEL LACTANTE   RECIEN NACIDO   ENFERMEDADES DEL RECIEN NACIDO   PREMATURO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MODELOS LINEALES   FACTORES DE TIEMPO   AUMENTO DE PESO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4127
Tipo de Material:
Separata




4/7
Serum insulin like growth factor 1 in congenital heart disease / JS Barton; PC Hindmarsh; MA Preece.-- pp.162-163.-- En: Archives of Disease in Childhood.-- 75, 2 (1996)
MARCADORES BIOLOGICOS   INDICE DE MASA CORPORAL   INGESTION DE ENERGIA   FEMENINO   CRECIMIENTO   CARDIOPATIAS CONGENITAS   HUMANO   LACTANTE   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   MASCULINO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-5097
Tipo de Material:
Separata

Ver separata



5/7
IGF-I, IGF-II, free IGF-I and IGFBP-1, -2 and -3 levels in venous cord blood: relationship to birthweight, length and gestational age in healthy newborns / D Klauwer; WF Blum; S Hanitsch; W Rascher; PD Lee; W Kiess.-- pp. 826-33.-- En: Acta Paediatrica: an International Journal of Paediatrics.-- 86, 8 (1997)
PESO AL NACER   SANGRE FETAL   EDAD GESTACIONAL   RECIEN NACIDO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA 2 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   PROTEINA DE ENLACE DE FACTOR DE CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6039
Tipo de Material:
Separata

    The insulin-like growth factors (IGF-I and IGF-II) and their binding proteins (IGFBPs) have been implicated in regulating fetal growth and development. The aim of this study was to determine whether fetal IGFs correlate with auxologic data at birth and/or gestational age. Venous cord blood was obtained from 138 healthy newborns immediately after birth and clinical data were recorded using a standardized data sheet. For the determination of IGF-I and IGF-II, IGFBP-blocked radioimmunoassays were used. A coated-tube immunoradiometric assay was applied for the measurement of free IGF-I. IGFBP-1, -2, and -3 were measured using specific radioimmunoassays. IGF-I levels were 61 +/- 21 ng ml(-1), median 61 ng ml(-1), range 19-114 ng ml(-1); IGF-II levels were 466 +/- 80 ng ml(-1), median 457 ng ml(-1), range 311-701 ng ml(-1); free IGF-I levels were 2.4 +/- 1.8 ng ml(-1), median 1.8 ng ml(-1), range 0.4-7.8 ng ml(-1). The concentration of IGFBP-1 was 144 +/- 110 ng ml(-1), median 113 ng ml(-1), range 20-626 ng ml(-1); that of IGFBP-2 was 1165 +/- 455 ng ml(-1), median 1119 ng ml(-1), range 440-3466 ng ml(-1). IGFBP-3 levels were 1272 +/- 280 ng ml(-1), median 1272 ng ml(-1), range 600-1966 ng ml(-1). IGF-I levels correlated significantly with IGFBP-3 levels (r = 0.71), birthweight (r = 0.48) and birth length (r = 0.37). There were significant inverse correlations between IGF-I and both IGFBP-1 (r = -0.45) and IGFBP-2 (r = -0.62). Although free IGF-I levels correlated (r = 0.71) with total IGF-I, only marginally significant correlations were found between free IGF-I and birthweight (r = 0.25)...Continúa.




6/7
High-dose growth hormone treatment of short children born small for gestational age / F de Zegher; M Maes; SE Gargosky; C Heinrichs; MV Du Caju; G Thiry.-- pp. 1887-92.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 81, 5 (1996)
ESTATURA   PREESCOLAR   TRASTORNOS DEL CRECIMIENTO   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   RECIEN NACIDO PEQUEÑO PARA LA EDAD GESTACIONAL   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   OSTEOCALCINA   AUMENTO DE PESO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6042
Tipo de Material:
Separata

    The effect of GH administration was evaluated over 2 yr in 50 short, prepubertal, non-GH deficient children born small for gestational age, who had been randomly allocated to a group receiving no treatment or daily sc GH treatment at a dose of 0.2 or 0.3 IU/kg. At the start of the study, mean age was 5.2 yr, bone age was 4.0 yr, height SDS was -3.5, height velocity SDS was -0.8, weight SDS was -2.7, and body mass index SDS was -1.9. Catch-up growth was observed in none of the untreated and all of the treated children. The response to GH treatment included a near doubling of growth velocity and of weight gain and a mean height increment of more than 2 SDS. GH treatment was associated with a distinct acceleration of bone maturation. The differences between the growth responses evoked by the two GH doses were minor. The prepubertal GH-induced catch-up growth was associated with elevated serum concentrations of insulin, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and osteocalcin, whereas insulin-like growth factor-II levels remained unaltered. GH treatment was well tolerated. In conclusion, high-dose GH administration over 2 yr is emerging as a potential therapy to increase the short stature that results from insufficient catch-up growth in young children born small for gestational age. The long-term impact of this approach remains to be delineated.




7/7
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society .-- pp. 3990-3.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 85, 11 (2000)
ADOLESCENTE   NIÑO   DIAGNOSTICO DIFERENCIAL   TRASTORNOS DEL CRECIMIENTO   HORMONA DEL CRECIMIENTO   RECIEN NACIDO   PROTEINA 3 DE ENLACE A FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   TAMIZAJE NEONATAL
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6053
Tipo de Material:
Separata





7 Registros recuperados

Presentar con el formato: 

Ver selección       Limpiar selección